- Home
- AGMH vs CALC Comparison
AGMH vs CALC Comparison
Compare AGMH & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- CALC
- Stock Information
- Founded
- AGMH 2015
- CALC 2011
- Country
- AGMH Hong Kong
- CALC United States
- Employees
- AGMH N/A
- CALC N/A
- Industry
- AGMH EDP Services
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- CALC Health Care
- Exchange
- AGMH Nasdaq
- CALC Nasdaq
- Market Cap
- AGMH 42.4M
- CALC 44.7M
- IPO Year
- AGMH 2018
- CALC N/A
- Fundamental
- Price
- AGMH $1.72
- CALC $3.35
- Analyst Decision
- AGMH
- CALC Strong Buy
- Analyst Count
- AGMH 0
- CALC 4
- Target Price
- AGMH N/A
- CALC $19.50
- AVG Volume (30 Days)
- AGMH 57.4K
- CALC 89.5K
- Earning Date
- AGMH 12-27-2024
- CALC 11-13-2024
- Dividend Yield
- AGMH N/A
- CALC N/A
- EPS Growth
- AGMH N/A
- CALC N/A
- EPS
- AGMH N/A
- CALC N/A
- Revenue
- AGMH $92,907,172.00
- CALC N/A
- Revenue This Year
- AGMH N/A
- CALC N/A
- Revenue Next Year
- AGMH N/A
- CALC N/A
- P/E Ratio
- AGMH N/A
- CALC N/A
- Revenue Growth
- AGMH N/A
- CALC N/A
- 52 Week Low
- AGMH $0.47
- CALC $2.68
- 52 Week High
- AGMH $2.20
- CALC $8.38
- Technical
- Relative Strength Index (RSI)
- AGMH 51.43
- CALC 40.56
- Support Level
- AGMH $1.68
- CALC $3.35
- Resistance Level
- AGMH $1.88
- CALC $3.60
- Average True Range (ATR)
- AGMH 0.13
- CALC 0.26
- MACD
- AGMH -0.02
- CALC -0.03
- Stochastic Oscillator
- AGMH 32.36
- CALC 4.35
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.